GSK3884464
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
May 02, 2024
A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=27 | Terminated | Sponsor: GlaxoSmithKline | N=12 ➔ 27
Enrollment change • Cardiovascular • Heart Failure
August 21, 2023
A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=12 | Terminated | Sponsor: GlaxoSmithKline | N=51 ➔ 12 | Trial completion date: Nov 2023 ➔ Aug 2023 | Recruiting ➔ Terminated; To allow for additional assessments from supplementary non-clinical activities.
Enrollment change • Trial completion date • Trial termination • Cardiovascular • Heart Failure • NQO1
November 07, 2022
A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=51 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Feb 2023 ➔ Nov 2023 | Trial primary completion date: Feb 2023 ➔ Nov 2023
Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure • NQO1
June 03, 2022
A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=51 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Sep 2022 ➔ Feb 2023 | Trial primary completion date: Sep 2022 ➔ Feb 2023
Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure • NQO1
December 30, 2021
A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants
(clinicaltrials.gov)
- P1; N=51; Recruiting; Sponsor: GlaxoSmithKline; Trial completion date: Oct 2022 ➔ Jul 2022; Trial primary completion date: Oct 2022 ➔ Jul 2022
Clinical • Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure • NQO1
October 27, 2021
A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants
(clinicaltrials.gov)
- P1; N=51; Recruiting; Sponsor: GlaxoSmithKline; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Cardiovascular • Heart Failure • NQO1
September 14, 2021
A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants
(clinicaltrials.gov)
- P1; N=51; Not yet recruiting; Sponsor: GlaxoSmithKline
Clinical • New P1 trial • Cardiovascular • Heart Failure • NQO1
1 to 7
Of
7
Go to page
1